Specify Company / Ticker to Get the Summary
Dividend History RLMD
Dividend Analytics RLMD
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Relmada Therapeutics Inc
RLMDRelmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida. Address: 2222 Ponce de Leon Blvd., Coral Gables, FL, United States, 33134
Analytics
WallStreet Target Price
1.00 USDP/E Ratio
–Dividend Yield
–Financials RLMD
Results | 2019 | Dynamics |